Abstract
Background Health outcomes from the COVID-19 pandemic vary widely across countries – by 2022 New Zealand suffered ∼10 total deaths per million people, whereas the U.K. and U.S. have had over 2000. Differences in infection fatality rates are insufficient to explain such vastly divergent outcomes. We propose that endogenous behavioral responses to risk shape countries’ epidemic trajectories, and that differences in responsiveness to risk are a primary driver of variation in epidemic scale and resultant mortality.
Methods We develop several testable predictions based on the proposed endogenous risk response mechanism. We test these using a simple modified SEIR model incorporating this mechanism, which we estimate for 131 countries (5.96 billion people) using data on daily reported SARS-CoV-2 infections and COVID-19 deaths. We further examine associations between COVID-19 deaths and several observed and model-estimated country characteristics using linear regression.
Findings We find empirical support for all predictions tested: 1) endogenous risk response substantially improves an SEIR model’s fit to data (mean absolute errors normalized by mean=66% across countries, vs. 551% without endogenous risk response); 2) Re converges to ∼1 across countries in both empirical data and model estimates with endogenous risk response (but not without it); 3) most cross-country variation in death rates cannot be explained by intuitively important factors like hospital capacity or policy response stringency; and 4) responsiveness to risk, which governs the sensitivity of the endogenous risk response, correlates strongly with death rates (R2=0.75) and is the strongest explanatory factor for cross-country variation therein.
Interpretation Countries converge to policy measures consistent with Re∼1 (or exponentially growing outbreaks will compel them to increase restrictions). Responsiveness to risk, i.e. how readily a country adopts the required measures, shapes long-term cases and deaths. With greater responsiveness, many countries could considerably improve pandemic outcomes without imposing more restrictive control policies.
Funding None.
Evidence before this study While numerous studies have examined drivers of variation in COVID-19 infection fatality rates (e.g. age, comorbidities), relatively few have sought to explain cross-country variation in overall mortality outcomes. Mortality outcomes are shaped primarily by variation in infection rates and only secondarily by IFR variation, yet the drivers of cross-country variation in infection rates are poorly understood as well. There is ample evidence that policy responses such as mask mandates, quarantines, and other non-pharmaceutical interventions (NPIs) can influence transmission, yet across countries the association of policy responses with long-term infection rates remains weak.
Added value of this study We propose a simple and intuitive theoretical mechanism – endogenous behavioral response to risk – to explain variation in cases and deaths across countries. While simple, the implications of this mechanism are rarely examined; a recent review found only 1 of 61 models in the CDC COVID-19 Forecast Hub incorporates endogenous risk response. We demonstrate how it can explain several empirical regularities, including multiple outbreak waves and convergence in effective reproduction number, which existing models largely do not explain. Our empirical estimates of responsiveness to risk also show that it drives wide cross-country variation in mortality outcomes, which otherwise remains unexplained.
Implications of all the available evidence Our results highlight the key role of responsiveness to risk in shaping COVID-19 mortality outcomes. They suggest that adopting similar policy responses but with greater responsiveness could improve outcomes and reduce mortality. The responsiveness mechanism also resolves the apparent paradox that despite clear evidence of proximal NPI effectiveness, their impact on infection and death outcomes in cross-country comparisons is rather weak. Our results highlight the need to understand better the determinants of differences in responsiveness across countries, and how to improve it.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research used no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Only public data sources used
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.